No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia-Reference-Cited by-同舟云学术

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

Published:2013-08-20 Issue:2 Volume:32 Page:87-93
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Racil Zdenek¹²³,Razga Filip¹⁴,Klamova Hana⁵,Voglova Jaroslava⁶,Belohlavkova Petra⁶,Malaskova Ludmila⁷,Potesil David³,Muzik Jan⁸,Zackova Daniela¹²,Polakova Katerina Machova⁵,Zdrahal Zbynek³⁹,Malakova Jana¹⁰,Suttnar Jiri⁵,Dyr Jan⁵,Mayer Jiri¹²³

Affiliation:

1. Department of Internal Medicine, Hematology and Oncology; University Hospital Brno; Brno Czech Republic

2. Faculty of Medicine; Masaryk University; Brno Czech Republic

3. CEITEC - Central European Institute of Technology; Masaryk University; Brno Czech Republic

4. Department for Biomaterials Research; Polymer Institute of the Slovak Academy of Sciences; Bratislava Slovakia

5. Institute of Hematology and Blood Transfusion; Prague Czech Republic

6. IV. Department of Internal Medicine - Hematology; University Hospital Hradec Kralove; Hradec Kralove Czech Republic

7. Department of Clinical Biochemistry; University Hospital Brno; Brno Czech Republic

8. Institute of Biostatistics and Analyses; Masaryk University; Brno Czech Republic

9. National Centre for Biomolecular Research, Faculty of Science; Masaryk University; Brno Czech Republic

10. Institute of Clinical Biochemistry and Diagnostics; Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove; Hradec Kralove Czech Republic

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2091/fullpdf

Reference17 articles.

1. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia;Hochhaus;Leukemia,2009

2. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase;Takahashi;Pharmacology,2011

3. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia;Picard;Blood,2007

4. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study;Larson;Blood,2008

5. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders;Singh;Eur J Clin Pharmacol,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis;Pharmacogenomics;2017-01

2. Combined cyto/genotoxic activity of a selected antineoplastic drug mixture in human circulating blood cells;Chemosphere;2016-12

3. Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?;Leukemia;2016-10-21

4. Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC–UV or LC–MS/MS methods;Drug Metabolism and Pharmacokinetics;2016-02

5. Erratum: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia;Hematological Oncology;2014-09